Gastroesophageal adenocarcinoma
Leap Therapeutics Inc. focuses on gastric adenocarcinoma and gastroesophageal junction cancer, with research centred on advanced and inoperable disease. Its clinical activity includes treatment settings for locally advanced and metastatic disease, reflecting interest in hard-to-treat upper gastrointestinal malignancies.
- Gastric cancer
- Gastroesophageal junction adenocarcinoma
- Advanced upper gastrointestinal cancer
The sponsor’s research in this area is linked to combination approaches involving immunotherapy and chemotherapy for patients with advanced disease.
Colorectal cancer
The company also funds studies in advanced colorectal cancer, including disease subsets defined by tumour location such as left-sided colorectal cancer. This area of interest covers patients whose disease has progressed beyond initial treatment, with attention to systemic therapy options used in later-line care.
- Advanced colorectal cancer
- Left-sided colorectal cancer
- Metastatic colorectal cancer
Research activity in this field is oriented toward regimens combining fluoropyrimidine– and oxaliplatin-based therapy with biologic treatment.
Tumour microenvironment and DKK1-related biology
Leap Therapeutics’ clinical portfolio includes cancers associated with DKK1-high disease, indicating a therapeutic interest in tumour pathways linked to cancer progression and immune response. This focus spans both gastroesophageal and colorectal malignancies.
- DKK1-high tumours
- Cancer signalling pathways
- Immune-related tumour biology
This area connects biomarker-informed patient selection with treatment strategies for advanced solid tumours.
Combination systemic therapy
The sponsor’s trials involve combination systemic treatment across gastrointestinal cancers, bringing together checkpoint inhibition, chemotherapy, and anti-angiogenic therapy. The research landscape therefore includes both immune-based and cytotoxic approaches in advanced solid tumours.
- Checkpoint inhibitor therapy
- Anti-angiogenic treatment
- Combination oncology regimens
These studies are concentrated in the United States and involve multiple collaborating research sites.
